Terkko Navigator / Hemminki, A(kseli)*

Cervical, vaginal and vulvar cancer incidence and survival trends in Denmark, Finland, Norway and Sweden with implications to treatment

Familial Risks for Liver, Gallbladder and Bile Duct Cancers and for Their Risk Factors in Sweden, a Low-Incidence Country

Long-term incidence in hepatocellular carcinoma and intrahepatic bile duct cancer in Denmark, Finland, Norway and Sweden, role of Thorotrast?

Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer

Long-term incidence and survival trends in cancer of the gallbladder and extrahepatic bile ducts in Denmark, Finland, Norway and Sweden with etiological implications related to Thorotrast

Oncolytic adenovirus decreases the proportion of TIM-3⁺ subset of tumor-infiltrating CD8⁺ T cells with correlation to improved survival in patients with cancer

Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1

Survival in bladder and upper urinary tract cancers in Finland and Sweden through 50 years

Incidence, mortality and survival in malignant pleural mesothelioma before and after asbestos in Denmark, Finland, Norway and Sweden

Types of second primary cancer influence overall survival in cutaneous melanoma

Familial Risks and Proportions Describing Population Landscape of Familial Cancer

Second Primary Cancers After Liver, Gallbladder and Bile Duct Cancers, and These Cancers as Second Primary Cancers

Adenoviral CD40 Ligand Immunotherapy in 32 Canine Malignant Melanomas-Long-Term Follow Up

Adenovirus Armed With TNFa and IL2 Added to aPD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to aPD-1

Treatment of Advanced Renal Cell Carcinoma: Immunotherapies Have Demonstrated Overall Survival Benefits While Targeted Therapies Have Not

Survival in colon and rectal cancers in Finland and Sweden through 50 years

Second Primary Cancers After Gastric Cancer, and Gastric Cancer as Second Primary Cancer

Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden

Oncolytic Adenovirus Coding for a Variant Interleukin 2 (vIL-2) Cytokine Re-Programs the Tumor Microenvironment and Confers Enhanced Tumor Control

Incidence trends in lung and bladder cancers in the Nordic Countries before and after the smoking epidemic

Incidence trends in bladder and lung cancers between Denmark, Finland and Sweden may implicate oral tobacco (snuff/snus) as a possible risk factor

Systemic Delivery of Oncolytic Adenovirus to Tumors Using Tumor-Infiltrating Lymphocytes as Carriers

Cytokine-Coding Oncolytic Adenovirus TILT-123 Is Safe, Selective, and Effective as a Single Agent and in Combination with Immune Checkpoint Inhibitor Anti-PD-1

Oncolytic Adenovirus ORCA-010 Activates Proinflammatory Myeloid Cells and Facilitates T Cell Recruitment and Activation by PD-1 Blockade in Melanoma

Oncolytic Adenovirus Type 3 Coding for CD40L Facilitates Dendritic Cell Therapy of Prostate Cancer in Humanized Mice and Patient Samples

Cancer Predisposition Genes in Cancer-Free Families

Rate differences between first and second primary cancers may outline immune dysfunction as a key risk factor

Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition

Ad5/3 is able to avoid neutralization by binding to erythrocytes and lymphocytes

Incidence Differences Between First Primary Cancers and Second Primary Cancers Following Skin Squamous Cell Carcinoma as Etiological Clues

Informing patients about their mutation tests: CDKN2A c.256G>A in melanoma as an example

Oncolytic viruses for cancer immunotherapy

Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid Tumors

TNFa and IL2 Encoding Oncolytic Adenovirus Activates Pathogen and Danger-Associated Immunological Signaling

Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

Second Primary Cancers in Melanoma Patients Critically Shorten Survival

Modulation of the tumor microenvironment with an oncolytic adenovirus for effective T-cell therapy and checkpoint inhibition

Association between tumor characteristics and second primary cancers with cutaneous melanoma survival: A nationwide cohort study

Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity

Influence of family history on risk of second primary cancers and survival in patients with squamous cell skin cancer

Constitutively active GSK3β as a means to bolster dendritic cell functionality in the face of tumour-mediated immune suppression

Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension

Familial Risks and Mortality in Second Primary Cancers in Melanoma

Second Primary Cancers in Patients with Invasive and In Situ Squamous Cell Skin Carcinoma, Kaposi Sarcoma, and Merkel Cell Carcinoma: Role for Immune Mechanisms?

Second primary cancers in non-Hodgkin lymphoma: Family history and survival

Types of second primary cancers influence survival in chronic lymphocytic and hairy cell leukemia patients

Oncolytic adenoviruses: a game changer approach in the battle between cancer and the immune system

Second primary cancers in patients with acute lymphoblastic, chronic lymphocytic and hairy cell leukaemia

Effect of Genetic Modifications on Physical and Functional Titers of Adenoviral Cancer Gene Therapy Constructs

Familial Associations of Colon and Rectal Cancers With Other Cancers